CD20, the protein which is expressed on the surface of all mature B cells, is active in many
B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL),
the most frequently occurring subtype of non-Hodgkin lymphomas. In clinical practice,
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone combination chemotherapy (CHOP) is
still considered one of the standard treatment to DLBCL. CMAB304(Retuxira), the chimeric
monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases.
This trial aimed to observe the safety and efficacy of CMAB304, by added CMAB304 to CHOP
chemotherapy regimen compared with CHOP chemotherapy alone.